α-Santalol (i.p. 12.5 mg/kg, 25 mg/kg, 50 mg/kg) prolongs the sleeping time more than β-Santalol when they were each administered intragastrically in male ddY mice[3].
α-Santalol (i.p. 12.5 mg/kg, 25 mg/kg, 50 mg/kg) reduces rectal temperature in a dose-related manner following i.p. administration and the magnitude of activity is greater than that of β-Santalol in male ddY mice [3].
α-Santalol and β-Santalol (p.o., 50 mg/kg, 100 mg/kg, 200 mg/kg) shows significant antinociceptive activities in male ddY mice[3].
α-Santalol and β-Santalol (i.p., 50 mg/kg) decreases spontaneous activity and simultaneously shows motor incoordination, such as catalepsy, but does not cause ptosis, hypnosis and muscle relaxation in male ddY mice [3].
α-Santalol (i.p., 25 mg/kg, 50 mg/kg) causes a greater reduction in methamphetamine-induced (at 2 mg/kg) motilities than β-Santalol in male ddY mice [3].
α-Santalol and β-Santalol (i.p., 25 mg/kg, 50 mg/kg) significantly decreases apomorphine-induced (2 mg/kg) movements in male ddY mice [3].
α-Santalol (i.p., 50 mg/kg) significantly increases the levels of HVA (homovanillic acid), and 5-HIAA (5-hydroxyindoleacetic acid) in the brain of treated mice[3].
β-Santalol (i.p., 50 mg/kg) increases the levels of DOPAC (3,4-dihydroxyphenylacetic acid), and 5-HT(serotonin creatinine sulfate) besides HVA and 5-HIAA in male ddY mice[3].
